|
Minimal Residual Disease Testing |
|
Detection of minimal residual disease is accomplished through quantitative PCR, a technology that can provide at least 100 to 1000 times greater sensitivity than FISH. Additional studies using gene sequencing also assist in determining acquired drug resistance as is the case in Gleevec®-resistant chronic myeloid leukemia.
 Test Information and Specimen Requirements
• Quantitative BCR/ABL by PCR »
• ABL Gene mutation for Gleevec® resistance »
• Quantitative PML/RARA by PCR »
Resources
 Advanced, complementary technologies
Specimen collection for quantitative PCR assays
Click here for BCR.ABL International scoring FAQ
For more information about minimal residual disease testing, contact one of our service specialists at 800.932.2943.
Journal Articles
1. Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K, Zehnder J. (2009). Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.J Mol Diagn 11(1):4-11. Epub 2008 Dec 18
2. Quigley NB, Henley DC, Hubbard RA, Laudadio J, Press RD (2008). ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. J Mol Diagn 10(5):475-6; Epub 2008 Aug 7
|
